U.S. patent application number 13/362502 was filed with the patent office on 2012-05-24 for heterogeneous yarns for surgical articles.
This patent application is currently assigned to Tyco Healthcare Group LP. Invention is credited to John J. Kennedy, Mark S. Roby, Joshua Stopek.
Application Number | 20120125527 13/362502 |
Document ID | / |
Family ID | 43126904 |
Filed Date | 2012-05-24 |
United States Patent
Application |
20120125527 |
Kind Code |
A1 |
Kennedy; John J. ; et
al. |
May 24, 2012 |
Heterogeneous Yarns For Surgical Articles
Abstract
Heterogeneous yarns containing strands of dissimilar materials
are useful in forming surgical device.
Inventors: |
Kennedy; John J.; (Guilford,
CT) ; Stopek; Joshua; (Yalesville, CT) ; Roby;
Mark S.; (Killingworth, CT) |
Assignee: |
Tyco Healthcare Group LP
North Haven
CT
|
Family ID: |
43126904 |
Appl. No.: |
13/362502 |
Filed: |
January 31, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12504954 |
Jul 17, 2009 |
|
|
|
13362502 |
|
|
|
|
10917183 |
Aug 12, 2004 |
|
|
|
12504954 |
|
|
|
|
60494993 |
Aug 14, 2003 |
|
|
|
Current U.S.
Class: |
156/167 ;
156/180 |
Current CPC
Class: |
D02G 3/448 20130101;
D10B 2509/00 20130101; D10B 2321/02 20130101; C08L 2203/12
20130101; A61L 17/105 20130101; A61L 31/125 20130101; A61L 31/125
20130101; D10B 2331/04 20130101; D04C 1/12 20130101; C08L 67/02
20130101; C08L 23/06 20130101; A61L 31/129 20130101; A61L 31/125
20130101; D04C 1/02 20130101; D10B 2509/04 20130101; C08L 67/00
20130101; D10B 2403/0311 20130101; C08L 23/06 20130101 |
Class at
Publication: |
156/167 ;
156/180 |
International
Class: |
D04H 3/12 20060101
D04H003/12; D04H 3/08 20060101 D04H003/08 |
Claims
1. A method of manufacturing a yarn for use with a surgical device
comprising: positioning a plurality of heterogeneous strands in
side-by-side fashion such that the plurality of heterogeneous
strands are maintained in a parallel relation to one another;
applying a binding agent to the plurality of heterogeneous strands;
and setting the binding agent.
2. A method according to claim 1, further comprising forming the
heterogeneous strands via an extrusion process.
3. A method according to claim 2, wherein the plurality of
heterogeneous strands are extruded to a length from about 5 inches
to about 144 inches.
4. A method according to claim 1, wherein positioning the plurality
of heterogeneous strands occurs within a holding receptacle
configured to maintain the plurality of heterogeneous strands in
the parallel relation to one another.
5. A method according to claim 4, wherein the holding receptacle is
a forming sheath.
6. A method according to claim 4, wherein the holding receptacle is
a permanent sheath that is applied to a surface of the plurality of
heterogeneous strands.
7. A method according to claim 4, wherein the holding receptacle is
made from the same material as the plurality of heterogeneous
strands.
8. A method according to claim 1, wherein setting the binding agent
occurs by heating the binding agent.
9. A method according to claim 8, wherein heating the binding agent
occurs at a temperature from about 70.degree. C. to about
160.degree. C.
10. A method according to claim 8, wherein heating the binding
agent occurs at a temperature from about 100.degree. C. to about
140.degree. C.
11. A method according to claim 8, wherein heating the binding
agent further comprises tensioning the plurality of heterogeneous
strands to facilitate maintaining the parallel relation of the
plurality of heterogeneous strands with respect to one another.
12. A method according to claim 1, wherein the binding agent is
applied along the entire length of the plurality of heterogeneous
strands.
13. A method according to claim 1, wherein the binding agent is
applied along discrete locations along the length of the plurality
of heterogeneous strands.
14. A method according to claim 1, wherein the binding agent is
selected from the group consisting of biocompatible adhesives,
thermoplastic resins, waxes, and combinations thereof.
15. A method according to claim 14, wherein the biocompatible
adhesives are selected from the group consisting of synthetic
absorbable and non-absorbable monomers and oligomers.
16. A method according to claim 15, wherein the synthetic
absorbable and non-absorbable monomers and oligomers are selected
from the group consisting of lactic acid, glycolic acid,
caprolactone, dioxanone, polyethylene glycol (PEG), polypropylene
glycol, isocyanates, copolymers thereof, and combinations
thereof.
17. A method according to claim 1, wherein positioning the
plurality of heterogeneous strands in side-by-side fashion forms a
corresponding plurality of interstices between the plurality of
heterogeneous strands.
18. A method according to claim 17, wherein the plurality of
interstices are configured to provide an area for receiving the
binding agent therein.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a divisional of, and claims the
benefit of and priority to, co-pending U.S. patent application Ser.
No. 12/504,954 filed on Jul. 17, 2009, which is a
continuation-in-part of, and claims the benefit of and priority to,
U.S. patent application Ser. No. 10/917,183 filed on Aug. 12, 2004,
now abandoned, which claims priority to and the benefit of U.S.
Provisional Application No. 60/494,993 filed on Aug. 14, 2003, the
entire disclosures of each of which are hereby incorporated by
reference in their entirety.
BACKGROUND
[0002] 1. Technical Field
[0003] The present disclosure relates to yarns made of dissimilar
materials. Filaments of at least two dissimilar materials are
combined to form a yarn which, in turn, can be braided, woven, etc.
to form a device suitable for surgical use.
[0004] 2. Background of Related Art
[0005] Sutures intended for the repair of body tissues must meet
certain requirements; they must be substantially non-toxic, capable
of being readily sterilized, they must have good tensile strength
and have acceptable knot-tying and knot-holding characteristics
and, if the sutures are of the bio-absorbable variety, the
bio-absorption of the suture must be closely controlled.
[0006] Sutures have been constructed from a wide variety of
materials including surgical gut, silk, cotton, polyolefins such as
polypropylene, polyamides, polyesters such as polyethylene
terephthalate, polyglycolic acid, glycolide-lactide copolymer, etc.
Sutures have been constructed from these materials in a
monofilament form and as braided structures. For example, sutures
manufactured from silk, polyamide, polyester and bio-absorbable
glycolide-lactide copolymer are typically provided as
multi-filament braids.
[0007] Filaments have also been utilized to form other
mutli-filament surgical or medical devices, such as braided tapes,
gauze, wound dressings, hernial repair meshes, vascular grafts
(e.g. fabrics and/or tubes) anastomosis rings, prosthetic ligaments
and tendons, growth matrices, drug delivery devices and other
implantable medical devices. Multi-filaments braids typically
provide the advantages of enhanced pliability, and tensile strength
as compared to monofilament constructions, and where utilized as
sutures, posses enhanced knot security. The enhanced pliability of
a multi-filament braid is caused by a lower resistance to bending
of a strand of very fine filaments as opposed to one large diameter
monofilament. The individual filaments must be able to bend
unencumbered or unrestricted by their neighboring filaments. Any
mechanism which reduces this individual fiber mobility, such as
simple fiber-fiber friction, a coating which penetrates into the
braid interstices, or a melted polymer matrix which adheres fibers
together, could adversely affect braid pliability. It would be
advantageous to combine dissimilar materials or fibers to form
filament strands to enhance pliability and strength.
SUMMARY
[0008] The present disclosure relates to biocompatible composite
surgical devices made from heterogeneous yarns. The yarns contain
multiple strands of a polyester material and multiple strands of a
polyolefin material. The strands are combined in substantially
parallel lengths with respect to each other to form the
heterogeneous yarn. The yarns can then be braided, knitted or woven
to form medical/surgical devices, including sutures.
BRIEF DESCRIPTION OF DRAWINGS
[0009] FIG. 1 is a cross sectional view of a heterogeneous yarn of
polyester and polyolefin strands;
[0010] FIG. 2 shows a needle-suture combination in accordance with
the present disclosure;
[0011] FIG. 3 is a perspective view of a portion of a split human
sternum illustrating one application of the present invention for
retaining the split portions together to promote healing;
[0012] FIG. 4 is an enlarged view of the suture product shown in
FIG. 3 illustrating one embodiment wherein the elongated product is
a flat braided member and contains at least eight reinforcing
filaments extending along the length;
[0013] FIG. 5 is a view of an alternative embodiment of the suture
repair product wherein the elongated member is a spiroid braided
member having a generally circular cross-section containing at
least one elongated reinforcing member; and
[0014] FIG. 6 is a view of another alternative embodiment of the
suture repair product wherein the elongated product is a hollow
braided member having a generally circular cross-section and
contains at least one elongated reinforcing member extending
centrally thereof along the length.
DETAILED DESCRIPTION
[0015] The present disclosure relates to heterogeneous yarns, which
can be used in the fabrication in whole or in part of a variety of
textile surgical devices, including, for example, sutures, braided
tapes, gauze, wound dressings, hernial repair meshes, vascular
grafts (e.g. fabrics and/or tubes) anastomosis rings, prosthetic
ligaments and tendons, growth matrices, drug delivery devices and
other implantable medical devices. An implantable medical device is
defined as any device which can be implanted in an animal for
medical purposes. The yarns can be braided, knitted or woven to
form the devices.
[0016] In accordance with the present disclosure, at least two
different kinds of fibers or strands are placed in intimate contact
to form a heterogeneous yarn. More particularly, the heterogeneous
yarns contain strands made from a polyester and strands made from a
polyolefin. Multiple strands of polyester and polyolefin are
combined to form a single yarn. Multiple heterogeneous yarns thus
obtained are then braided, knitted, or woven to form a
multi-filament surgical/medical device, such as, for example, a
multi-filament surgical suture.
[0017] In particularly useful embodiments, the polyester strands
are made of polyethylene terephthalate. Polyethylene terephthalate
is a thermoplastic polyester formed by esterification from ethylene
glycol and terephthalic acid. Its advantageous properties include
high tensile strength, high resistance to stretching under both wet
and dry conditions, and good resistance to degradation by chemical
bleaches and to abrasion. Polyethylene terephthalate is
commercially available from DuPont Corporation, Wilmington, Del.,
under the trademark DACRON.RTM..
[0018] The polyolefin strands are preferably made from a
polyethylene. In particularly useful embodiments, the polyethylene
is an ultra high molecular weight polyethylene. Ultra high
molecular weight ("UHMW") polyethylene is a linear polymer with an
average molecular weight greater than about 400,000, typically in
the range of about 500,000 to about 6,000,000. UHMW polyethylene
has a high tenacity and low elongation rate to provide articles
with greatly increased strength and decreased elongation.
[0019] UHMW polyethylene typically exhibits a very substantial
degree of crystalline orientation (95-99%) and crystalline content
(60-85%). The significant strength and stability of UHMW
polyethylene is normally caused by the high degree of molecular
orientation. As a result, the fibers exhibit strengths from about
375 kpsi (thousands of pounds per square inch) to about 560 kpsi,
and tensile moduli of about 15 msi (millions of pounds per square
inch) to about 30 msi. Ultra high molecular weight polyethylene is
commercially available under the trademark SPECTRA.RTM.. from
Allied-Signal Technologies, Petersburg, Va., and under the
trademark DYNEEMA.RTM. from DSM High Performance Fibers, JH
Heerlen, The Netherlands.
[0020] The yarn may optionally contain strands of other materials.
Materials used to construct these optional strands can include a
wide variety of natural and synthetic fibrous materials such as any
of those previously known for the construction of sutures. Such
materials include non-absorbable as well as partially and fully
bio-absorbable (i.e., resorbable) natural and synthetic
fiber-forming polymers, including thermoplastics. Suitable
non-absorbable materials can include, for example, polyamides,
polyesters such as polyethylene terephthalate, polyacrylonitrile,
polyolefins such as polyethylene and polypropylene, silk, cotton,
linen, etc. Carbon fibers, steel fibers and other biologically
acceptable inorganic fibrous materials can also be employed.
Bio-absorbable resins can include those derived from glycolic acid,
glycolide, lactic acid, lactide, dioxanone, epsilon-caprolactone,
trimethylene carbonate, etc., and various combinations of these and
related monomers.
[0021] The strands which form the yarns can be made using any known
technique, such as, for example, extrusion, molding and/or solvent
casting. In a preferred embodiment, the strands can be extruded
through an extruder unit of a conventional type, such as those
disclosed in U.S. Pat. Nos. 6,063,105; 6,203,564; and 6,235,869,
the contents of each of which are incorporated by reference herein.
The strands of dissimilar materials can be extruded separately and
subsequently brought together into a group to form a yarn, or the
strands can be extruded in a side-by-side fashion and collected
together to immediately form a yarn. The number of strands used per
yarn will depend on a number of factors including the desired final
size of the yarn and the ultimate multi-filament article being
produced. For example, with respect to sutures, size is established
according to United States Pharmacopoceia ("USP") standards.
However, each yarn can contain at least ten strands, and often
more, of at least two differing material types. The strands run
parallel to each other along the length of the yarn. Although
twisting the strands to form a twisted yarn is also
contemplated.
[0022] Turning now to FIG. 1, heterogeneous yarn 10 of the present
disclosure is shown. Yarn 10 may be formed, in embodiments
extruded, to any suitable length. More particularly, the extruded
length of the yarn 10 may be determined by the intent of use of the
yarn 10. For example, in the instance where the intended use of the
yarn 10 is for the manufacture of a suture 101, the yarn 10
includes a length that is at least equal to the length of the
suture (see FIG, 2, for example). In embodiments, yarn 10 may
include lengths that are from about 5 inches to about 144 inches.
For illustrative purposes, a segment of a yarn 10 is depicted in
FIG. 1 and includes a plurality of polyolefin strands 12 (such as,
UHMW polyethylene) and polyester strands 14 (such as DACRON.RTM.).
While only a segment of yarn 10 is depicted in FIG. 1, it is to be
understood that, in embodiments, the parallel orientation of
strands 12 and 14 may be maintained along the entire length of yarn
10 (not shown). In other words, the plurality of strands 12 and 14
run parallel to both each other and the longitudinal axis of yarn
10, along the length of yarn 10.
[0023] As noted above, yarn 10 may be formed by one or more known
extrusion processes. After the strands 12 and 14 have been extruded
and subsequently brought together and/or collected, each of the
strands 12 and 14 are arranged and maintained so that they are in
intimate contact with each other in a parallel relation relative to
one another. This parallel configuration of strands 12 and 14 may
increase the structural integrity of the yarn 10.
[0024] The strands 12 and 14 may be maintained in this parallel
relation by any suitable methods and/or processes. For example, in
an embodiment, the strands 12 and 14 may be temporarily positioned
within a holding receptacle, such as, for example, a removable
forming sheath (not shown). The forming sheath may be configured to
maintain the strands 12 and 14 in a parallel configuration during
the formation of the yarn 10.
[0025] In embodiments, after the strands 12 and 14 have been
positioned within the forming sheath, the strands 12 and 14 may be
subsequently bonded to each other by any means within the purview
of those skilled in the art. Such means may include, for example,
the application of heat, the use of binding agents, the use of
coatings, combinations thereof, and the like. In embodiments,
instead of a forming sheath, a permanent sheath may be applied to
the external surface of yarn 10, thereby assisting in maintaining
the parallel orientation of strands 12 and 14.
[0026] A sheath which is applied to the strands 12 and 14 and left
thereon to maintain their parallel orientation may be formed of any
materials used to form strands 12 and/or 14, as well as any other
component utilized to form a suture of the present disclosure.
[0027] Depending upon the materials utilized to form the strands,
in embodiments, suitable heating to fuse the strands together may
include heating to from about 70.degree. C. to about 160.degree.
C., in embodiments from about 100.degree. C. to about 140.degree.
C.
[0028] The heating may be dependent upon the glass transition
temperature of the materials utilized to form the strands.
Moreover, in embodiments, it may be desirable to heat the strands
under tension, to maintain the parallel orientation of the
strands.
[0029] Suitable binding agents are within the purview of those
skilled in the art and include suitable biocompatible adhesives,
thermoplastic resins, waxes, combinations thereof, and the like. In
embodiments, a plurality of interstices "I" may be formed between
the plurality of strands 12 and 14. The interstices "I" run
parallel to each other and the strands 12 and 14 along the length
of the yarn 10. In embodiments, the plurality of interstices may be
configured to provide an area for receiving the binding agent "A".
The binding agent "A" may be applied along the entire length of the
yarn, or in discrete locations along the length of the yarn. In
embodiments it may prove useful to apply the binding agent may be
deposited at specific locations or nodes "n" along the length of
the yarn, see FIG. 1. The plurality of nodes "n" and/or forming
sheath may be configured to receive the binding agent at
corresponding predetermined locations along the length of the yarn
10. The plurality of nodes "n" may be configured to maintain the
strands 12 and 14 in a fixed parallel relation relative to one
another.
[0030] Thus, in embodiments, a method for forming a yarn of the
present disclosure may include positioning a plurality of strands
in side-by-side fashion such that the plurality of strands are
maintained in a parallel relation relative to one another, applying
a binding agent to the plurality of heterogeneous strands, and
setting the binding agent to assist in maintaining the strands in
their parallel configuration.
[0031] Any biocompatible adhesive may be utilized. In embodiments,
suitable adhesive materials include synthetic absorbable and
non-absorbable monomers and oligomers including those synthesized
from materials such as lactic acid, glycolic acid, caprolactone,
dioxanone, polyethylene glycol (PEG), polypropylene glycol,
isocyanates, copolymers thereof, combinations thereof, and the
like. Adhesive materials may be combined with solvents for their
application, including polar and non-polar solvents. Suitable
solvents include alcohols, e.g., methanol, ethanol, propanol,
chlorinated hydrocarbons (such as methylene chloride, chloroform,
1,2-dichloro-ethane), and aliphatic hydrocarbons such as hexane,
heptene, ethyl acetate.
[0032] The specific manner in which the binding agent may be
applied to the yarn 10 will depend on the contemplated uses of the
suture. After the binding agent is applied to the strands 12 and
14, strands 12 and 14 and/or the binding agent may be set using
known curing methods or processes (e.g., ultra-violet curing) or
other suitable methods or processes not described herein.
[0033] In embodiments, the strands 12 and 14 and/or the binding
agent may be simultaneously subjected to an ultra-violet curing
process. Following the ultra-violet curing process, the forming
sheath may be subsequently removed, producing a yarn 10 that
includes the strands 12 and 14 in a fixed parallel
configuration.
[0034] In embodiments, after the strands 12 and 14 have been set or
formed in the fixed parallel configuration, the yarn 10 including
the strands 12 and 14 may be treated with a suitable coating (not
shown). In embodiments, the coating may be employed to facilitate
in maintaining the strands 12 and 14 in a parallel configuration.
Any biocompatible coating may be applied thereto, including those
disclosed in U.S. Patent Application Publication Nos. 2008/0268243,
2007/0207189, 2007/0010856, 2006/0188545, 2004/0153125, and
2004/0147629, and U.S. Pat. Nos. 6,878,757, 6,136,018, 6,007,565,
and 5,716,376, the entire disclosures of each of which are
incorporated by reference herein.
[0035] A coating and/or sheath may be applied in discrete locations
or, in embodiments, may be applied along the longitudinal distance
of the suture. Where applied in discrete locations, the locations
may be intermittent and/or discrete, or may be along one or more
partial lengths of continuous and/or increasing and/or decreasing
change in length along the suture.
[0036] Once formed, a plurality of the heterogeneous yarns 10 can
then be braided, knitted, or woven together. The braiding can be
done by any method known to those skilled in the art. For example,
braid constructions for sutures and other medical devices are
described in U.S. Pat. Nos. 5,019,093; 5,059,213; 5,133,738;
5,181,923; 5,226,912; 5,261,886; 5,306,289; 5,318,575; 5,370,031;
5,383,387; 5,662,682; 5,667,528; 6,203,564; the contents of each of
which are incorporated by reference herein. Once the suture is
constructed, it is preferably sterilized, by any means known to
those skilled in the art.
[0037] Braided surgical devices made using heterogeneous yarns
prepared in accordance with the disclosure can optionally be coated
with one or more coating compositions to improve functional
properties of the device. For example, a coating can be applied to
improve surface lubricity and knot tie-down behavior. Suitable
coating compositions include but are not limited to those disclosed
in U.S. Pat. Nos. 3,867,190; 3,942,532; 4,047,533; 4,452,973;
4,624,256; 4,649,920; 4,716,203; 4,826,945; and 5,569,302, the
disclosures of which are incorporated by reference herein. The
coating can be applied using any known technique such as, for
example coating, dipping, spraying or other appropriate
techniques.
[0038] The amount of coating composition applied to the device will
vary depending upon the specific construction of the device, its
size and the exact material of its construction. In general, the
coating composition will constitute from about 0.5 to about 4.0
percent by weight of the coated device or higher with a preferred
range from about 1.0 percent to about 3.0 percent.
[0039] A surgical device prepared from the presently described
heterogeneous yarns may also be impregnated with one or more
medico-surgically useful substances, e.g., those which accelerate
or beneficially modify the healing process when the suture is
applied to a wound or surgical site. The medically useful or
therapeutic agents can include varying amounts of one or more
optional ingredients, such as, for example, bioactive substances
such as biocidal agents, antibiotics, antimicrobials, medicants,
growth factors, anti-clotting agents, analgesic, anesthetics,
anti-inflammatory, etc., and the like. Medicants are defined as
substances which are beneficial to the animal and tend to promote
the healing process. For example, a braided suture can be provided
with a therapeutic agent which will be deposited at the sutured
site. The therapeutic agent can be chosen for its antimicrobial
properties, capability for promoting wound repair and/or tissue
growth, or for specific indications such as thrombosis.
Antimicrobial agents such as broad spectrum antibiotics (gentamicin
sulphate, erythromycin or derivatized glycopeptides) which are
slowly released into the tissue can be applied in this manner to
aid in combating clinical and sub-clinical infections in a surgical
or trauma wound site. To promote wound repair and/or tissue growth,
one or more biologically active materials known to achieve either
or both of these objectives can also be applied to the braided
suture. Such materials include any of several human Growth factors
(HGFs), magainin, tissue or kidney plasminogen activator to cause
thrombosis, superoxide dismutase to scavenge tissue-damaging free
radicals, tumor necrosis factor for cancer therapy, colony
stimulating factor, interferon, interleukin-2 or other lymphokines
to enhance the immune system, and so forth.
[0040] The braided device prepared from heterogeneous yarns in
accordance with this disclosure can also include, for example,
biologically acceptable plasticizers, antioxidants, and colorants,
which can be impregnated into the heterogeneous yarns of the
device.
[0041] In addition, the yarn and/or product may be plasma treated
depending upon the particular needs or intended application so as
to reduce the perceived "slipperiness" of the product as
desired.
[0042] The braided suture 101 prepared in accordance with this
disclosure can have a needle 102 attached thereto as shown in FIG.
2, to provide a needle suture combination 100. In order to
facilitate needle attachment, conventional tipping agents can be
applied to the braid. Two tipped ends of the suture may be
desirable for attaching a needle to each end of the suture to
provide a so-called double armed suture. The needle attachment can
be made by any conventional method such as crimping, swaging, etc.,
including those described in U.S. Pat. Nos. 5,133,738; 5,226,912;
and 5,569,302, the disclosures of which are incorporated by
reference herein.
[0043] As noted above the heterogeneous yarns of the present
disclosure can also be utilized to form other surgical or medical
articles, including, braided tapes, gauze, wound dressings, hernial
repair meshes, vascular grafts (e.g. fabrics and/or tubes)
anastomosis rings, prosthetic ligaments and tendons, growth
matrices, drug delivery devices and other implantable medical
devices.
[0044] Referring initially to FIG. 3 there is illustrated a sternum
closure ribbon 110 constructed according to the present invention
and positioned to retain portions 112, 114 of a human sternum 116
together. The band 110 is a braided product made from the
heterogeneous yarns described herein. In FIG. 4, the band 110 shown
in FIG. 3 is shown in greater detail as an elongated flat braided
textile product prepared as described in U.S. Pat. No. 5,318,575,
the disclosure of which is incorporated herein by reference, with
the exception that heterogeneous yarns in accordance with the
present disclosure are used in the construction.
[0045] Accordingly, it is possible in one application to position
the reinforced structure 110 about the split portions 112, 114 of
the human sternum 116 as shown in FIG. 3 whereby substantial force
may be applied to the band by tying the band either by a knot 122
shown in FIG. 3, or by other techniques whereby significant force
may be applied and retained to promote natural healing of the
sternum portions 112, 114, e.g. mechanical connecting devices such
as buckles, etc. See, for example, U.S. Pat. No. 4,813,416.
[0046] In FIG. 5, there is an alternative elongated embodiment of
spiroid braided construction of generally circular cross-section
and comprised of heterogeneous yarns 126 combined to form a braided
rope-like construction of generally circular cross-sectional
configuration. Braid constructions having a circular cross-section
are described in U.S. Pat. Nos. 3,565,077 and 5,019,093. In FIG. 6
there is shown a hollow braid construction 128 having a sheath
constructed of heterogeneous yarns 130 and having a core 132.
[0047] Surgical devices prepared from heterogeneous yarns in
accordance with this disclosure can be packaged and sterilized in
any conventional manner known to those skilled in the art.
[0048] It will be understood that various modifications may be made
to the embodiments disclosed herein. For example, in any of the
braided products described herein one or more of the yarns may be
heterogeneous yarns in accordance with this disclosure while the
remaining portions are made of absorbable or non-absorbable fibers
or filaments. As one illustrative example, for braided products
containing a core/sheath structure, the core may be a heterogeneous
yarns in accordance with this disclosure while the sheath yarns can
be made form other biocompatible fibers, including, but not
necessarily, bioabsorbable fibers. Therefore the above description
should not be construed as limiting, but merely as exemplications
of preferred embodiments. Those skilled in the art will envision
other modifications within the scope and spirit of the claims
appended hereto.
* * * * *